about
Risk-reducing medication for primary breast cancer: a network meta-analysisAspirin and Colorectal Cancer Prevention and Treatment: Is It for Everyone?Can Aspirin and Cancer Prevention be Ageless Companions?Gastric cancer: descriptive epidemiology, risk factors, screening, and preventionRecent developments in esophageal adenocarcinomaWhat is good for the circulation also lessens cancer riskA systematic review of aspirin in primary prevention: is it time for a new approach?Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiologyCOX-2 Inhibitors and Gastric CancerRepurposing of approved cardiovascular drugsThe evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimismNon-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening TrialEnvironmental risk factors for pancreatic cancer: an update.Analgesic medication use and risk of epithelial ovarian cancer in African American women.Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.Current strategies for the prevention of breast cancerAspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD)Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink.Modulation of age- and cancer-associated DNA methylation change in the healthy colon by aspirin and lifestyle.Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cellsScreening for and surveillance of gastric cancer.Analgesic use and the risk of kidney cancer: a meta-analysis of epidemiologic studiesStatins are associated with reduced risk of gastric cancer: a meta-analysis.Prevention and early detection of prostate cancer.Impact of acetylsalicylic Acid on the clinicopathological characteristics and prognosis of patients with invasive breast cancer.Estimates of benefits and harms of prophylactic use of aspirin in the general population.Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett's esophagus cohort.Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis.The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagusBID mediates selective killing of APC-deficient cells in intestinal tumor suppression by nonsteroidal antiinflammatory drugs.Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies.Aspirin Blocks EGF-stimulated Cell Viability in a COX-1 Dependent Manner in Ovarian Cancer CellsRisk factors for pancreatic cancer: a summary review of meta-analytical studies.Use of nonsteroidal anti-inflammatory drugs and bladder cancer risk: a meta-analysis of epidemiologic studiesFrequency-risk and duration-risk relationships between aspirin use and gastric cancer: a systematic review and meta-analysisAspirin use and knowledge in the community: a population- and health facility based survey for measuring local health system performance.Epidemiological study of prostate cancer (EPICAP): a population-based case-control study in FranceAspirin use and lung cancer risk: a possible relationship? Evidence from an updated meta-analysis.Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study.A large cohort study of nonsteroidal anti-inflammatory drugs and renal cell carcinoma incidence in the National Institutes of Health-AARP Diet and Health Study.
P2860
Q24185817-0A287A62-1659-46B4-9D76-AA35AA53256FQ26749127-E420CC7F-51FB-4A7E-86CC-3A309C3A3430Q26827455-90B75AD1-9AF7-4115-8839-0BD66F674EFDQ26849435-EDC0B4D1-D833-4544-A0F7-40D57BA15849Q26849652-85F3B95B-3188-4037-A775-C0D6E7E6C216Q26859261-4A91C366-83EA-4342-9C96-CAFEB76DE261Q26864015-4496F2B9-E0C4-4B64-BBDA-E727F1B593A4Q27011884-3AAA8815-5802-472F-BE3A-FC3B0F04A1F9Q27692701-6D12A2FD-EAD6-44D1-9BFF-FBE9C2E1C9AFQ28074453-671FE8B6-5E81-4D85-9E90-0F54FCD22024Q28087427-963839DB-CBBD-4AE4-B876-6434E44A319DQ28551492-092CD84D-8F81-4414-AB6C-87DA6BA0B872Q30248417-A6C315C3-BC06-4400-AD28-3D7805DDA5AFQ30277284-0873D2DE-14FB-44DD-8C91-1CE908AC4F9EQ30457290-DE40C0FF-9B3E-4FF9-87A3-0EE74FA88D2EQ33599463-9B039308-B263-4370-9F4F-FC3530F93967Q33648694-4ADE69DD-7169-4EFA-ACB7-61EF8AD1698CQ33739454-B7AA9951-C02C-4F84-80A3-5E23A0B2B527Q33958348-783E2C27-3287-4E4F-885D-E6D4775E9FC8Q34008634-B7BBA745-56EE-4179-B258-6B4B85C79E23Q34326563-F3B61F82-7370-4188-8C3D-99E22556A1EDQ34327296-09F78CCD-ACDC-42E7-AC26-014E49C00291Q34349560-603C9A57-B927-4522-A155-E17CEA186D33Q34371057-9903BFD0-95D6-488E-B3E2-CDFFF9337CE2Q34403601-482A6BF7-1459-49D9-A3FC-D27D912FDB5DQ34432503-04959E17-8AF8-4723-A8EC-D1D4B60C4341Q34457732-951BF3F3-ACEC-4E17-8C86-A19E3C25148EQ34458235-973F5DC6-3F85-4475-A8F0-B314FEFF8EB0Q34542075-136F26C2-64BF-4907-AB47-E6647535FA8DQ34581082-8C4B036A-D2FA-4D17-AF80-F9B414E5C2D8Q34603649-4A4B83C0-C2F4-4D5A-86A4-F983AC27577AQ34656901-A5961524-A70D-44EA-A319-DC77430D21AAQ34667061-7F35C283-DA99-4F55-BA2D-149AA21A4A3EQ34875118-B2CD8278-4B32-42A8-AC5D-48D33E6BD193Q34923812-E4CF2FFE-87B4-4824-A8D9-02E85C2FA55DQ35089003-82CE8550-A85D-485E-BDB1-DAD2FB8C5E66Q35098158-58F628A0-F21B-49B4-8872-D29BCF6FA8A4Q35306580-1A459AD0-5C9B-40A9-82E1-AB346140A910Q35711979-7B10C286-ED9E-4A9B-962F-0033F387368FQ35800256-B2F3D9EC-C7E1-42EE-8ADE-8BC2C406ACC2
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Aspirin and cancer risk: a quantitative review to 2011.
@ast
Aspirin and cancer risk: a quantitative review to 2011.
@en
Aspirin and cancer risk: a quantitative review to 2011.
@nl
type
label
Aspirin and cancer risk: a quantitative review to 2011.
@ast
Aspirin and cancer risk: a quantitative review to 2011.
@en
Aspirin and cancer risk: a quantitative review to 2011.
@nl
prefLabel
Aspirin and cancer risk: a quantitative review to 2011.
@ast
Aspirin and cancer risk: a quantitative review to 2011.
@en
Aspirin and cancer risk: a quantitative review to 2011.
@nl
P50
P356
P1433
P1476
Aspirin and cancer risk: a quantitative review to 2011.
@en
P2093
P304
P356
10.1093/ANNONC/MDS113
P577
2012-04-19T00:00:00Z